Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis | Zendy

Sander P. van Rijn | Zendy; Marlanka A. Zuur | Zendy; Richard Anthony | Zendy; Bob Wilffert | Zendy; Richard van Altena | Zendy; Onno W. Akkerman | Zendy; Wiel C.M. de Lange | Zendy; Tjip S. van der Werf | Zendy; Jos G.W. Kosterink | Zendy; JanWillem C. Alffenaar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis

Author(s) -

Sander P. van Rijn,

Marlanka A. Zuur,

Richard Anthony,

Bob Wilffert,

Richard van Altena,

Onno W. Akkerman,

Wiel C.M. de Lange,

Tjip S. van der Werf,

Jos G.W. Kosterink,

JanWillem C. Alffenaar

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01489-18

Subject(s) - ertapenem , meropenem , mycobacterium tuberculosis , tuberculosis , medicine , carbapenem , imipenem , tolerability , regimen , intensive care medicine , antibiotics , microbiology and biotechnology , antibiotic resistance , biology , adverse effect , pathology

Multi- and extensively drug-resistant tuberculosis (M/XDR-TB) has become an increasing threat not only in countries where the TB burden is high but also in affluent regions, due to increased international travel and globalization. Carbapenems are earmarked as potentially active drugs for the treatment ofMycobacterium tuberculosis .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research